NATCOPHARM — Natco Pharma Balance Sheet
0.000.00%
- IN₹147.98bn
- IN₹121.65bn
- IN₹44.30bn
- 89
- 53
- 27
- 60
Annual balance sheet for Natco Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4,241 | 4,061 | 7,931 | 13,912 | 24,899 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,904 | 8,380 | 10,336 | 14,217 | 15,755 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 23,373 | 24,972 | 30,003 | 40,235 | 52,700 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 22,372 | 23,084 | 23,034 | 24,350 | 26,573 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 47,919 | 51,091 | 56,574 | 69,063 | 86,308 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5,256 | 7,104 | 6,831 | 9,728 | 9,435 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 6,703 | 8,455 | 7,836 | 10,532 | 10,238 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 41,216 | 42,636 | 48,738 | 58,531 | 76,070 |
| Total Liabilities & Shareholders' Equity | 47,919 | 51,091 | 56,574 | 69,063 | 86,308 |
| Total Common Shares Outstanding |